- Home
- BJRI vs URGN Comparison
BJRI vs URGN Comparison
Compare BJRI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | URGN |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 922.1M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BJRI | URGN |
|---|---|---|
| Price | $44.03 | $21.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $39.80 | $29.50 |
| AVG Volume (30 Days) | 326.0K | ★ 799.3K |
| Earning Date | 02-20-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.21 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $1,388,066,000.00 | $96,516,000.00 |
| Revenue This Year | $5.06 | $26.47 |
| Revenue Next Year | $2.66 | $110.65 |
| P/E Ratio | $32.87 | ★ N/A |
| Revenue Growth | 3.85 | ★ 8.00 |
| 52 Week Low | $28.46 | $3.42 |
| 52 Week High | $47.02 | $30.00 |
Technical Indicators
Market Signals| Indicator | BJRI | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.66 | 49.03 |
| Support Level | $43.24 | $19.13 |
| Resistance Level | $45.15 | $22.21 |
| Average True Range (ATR) | 1.40 | 1.27 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 81.27 | 65.44 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.